Is definitive concurrent chemoradiotherapy effective for locally advanced head and neck cancer in the elderly aged ≥ 75 years: A single‐institute, retrospective, cohort study

Lai, Kuan-Ming; Lin, Jen-Tsun; Lu, Hsueh‐Ju; Liang, Chia-Chun; Chen, Mu‐Kuan

doi:10.1111/ajco.12764

Cited by 7 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our search criteria, 2543 papers were initially identified. After sorting and removal of duplicates, 82 papers that fully fit our inclusion criteria were retrieved, reviewed in detail, and summarized in Tables according to the modality of treatment used: RT, systemic therapy (CT or targeted therapy), surgery, or multimodal therapy …”

Section: Introductionmentioning

confidence: 99%

The role of age in treatment‐related adverse events in patients with head and neck cancer: A systematic review

et al. 2019

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is often diagnosed in advanced stage and therefore requires aggressive, multimodal treatment. Elderly patients are often excluded from standard therapy regimens purely based on age. This clinical review aims to collect all published data in the literature on treatment modality selection in elderly patients and on age-related adverse events following treatment of HNSCC. We performed a literature search for articles on the treatment of HNSCC in elderly patients. Most of the articles were retrospective studies with the consequent limitations. It can be concluded that age is not an absolute contraindication for intensive treatment and comorbidity is an important predictor of outcome, but not the only one. Despite the existence of multiple tools for pretreatment evaluation, there are not consistent data on their use.

show abstract

Section: Introductionmentioning

confidence: 99%

The role of age in treatment‐related adverse events in patients with head and neck cancer: A systematic review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…3-PS status :Our study observed a numerically better 3 years OS rate for patients who had a good PS (I) (60.7%) in comparison to PSII-III (42%), but this difference was not statistically significant (p=0.5). On the other hand, Lai et al 25 in their multivariate analysis for elderly HNC patients above 70 years found that PS above I was an independent factor for decreased OS HR was 2.312 (95%CI:1.176-4.546; P=0.015 1). Similarly, Sommers et al 26 confirmed that PS II and III associated with lower OS compared to PS0 HR was 3.14 (95% CI: 1.58-6.28 P=0.001).…”

Section: Factors Affecting Treatment Outcomementioning

confidence: 95%

Factors Influencing Treatment Outcome of Non-Nasopharyngeal Head and Neck Squamous Cell Carcinoma in Geriatric Patients

Riad

Diab

Kamal

et al. 2020

Ain Shams Medical Journal

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinoma (HNSCC) are a heterogeneous group of malignancy. Their incidenceincreases with age. Therefore, elderly HNSCC patients represent a large population who need special care and treatment considerations. Aim of work:To correlate clinicopathologic factors of nonnasopharyngeal HNSCC geriatric patients with disease free survival (DFS) and overall survival (OS). Patients and methods:A retrospective analysis of fifty nonnasopharyngeal HNSCC elderly patients (≥ 65 years) treated at the head and neck cancer unit at the clinical oncology department, Ain Shams University Hospitals from June 2014 to June 2019. The study correlatedpatients' age, comorbidities, tumor stage and Eastern Cooperative Oncology Group performance state (ECOG PS) with disease free survival (DFS) and overall survival (OS). Results:Three years DFS rate among the patients aged 65-75 years was 73% versus 40% among patients aged 76-80 years and three years OS rate decreased from 48.2% to 40% respectively. The median OS was 39.5 months for patients without co-morbidities compared to 32.5 months for patients with associated co-morbidities (P=0.9) and the median DFS was nearly about 40 months for both groups (p=0.7).Three years DFS was 78.7% among the patients with PS I and 54% among PS II and III (P=0.56) while three years OS rate was 60.7% among patients with PS I but it was 42% for PS II and III (p=0.5). The mean DFS dropped from 43.9 months to 18.4 months for early stages and locally advanced respectively but with no statistical significance association (P=0.49). There was marked decrease of 2years OS from 100% for early stages to 40.3% for locally advanced stages (p=0.009). Conclusion: In HNSCC geriatric patients age >75 years and locally advanced stages were poor prognostic factors for DFS and OS while co-morbidities and ECOG PS didn't affect treatment outcome.

show abstract

“…[ 46 ] 2018 R 158 65 HNC CRT 70.6 29 3-year OS 50% G > 3 hematological toxicity (18) - Lai et al. [ 63 ] 2018 R 70 75 HNC CRT 60-74/30-37 - Median OS 10.8 vs 11.4 months (CRT vs RT group) G3/4 hematological toxicities: neutropenia (13.2), thrombocytopenia (5.3) - Wang et al. [ 64 ] 2019 R 1061 74 (70–88) Cervical cancer CRT 50.4/28 + 30-36/5-7 28.9 3-year OS 71.9% G3/4 hematological toxicity (58.1) G3/4 GI toxicity (8.6) Jingu et al.…”

Section: Planning and Treatment In Older Patientsmentioning

confidence: 99%

Non-stereotactic radiotherapy in older cancer patients

Parisi

Lillo

Cacciola

et al. 2022

Heliyon

View full text Add to dashboard Cite

Is definitive concurrent chemoradiotherapy effective for locally advanced head and neck cancer in the elderly aged ≥ 75 years: A single‐institute, retrospective, cohort study

Abstract: Definitive RT with or without systemic chemotherapy did not significantly influence DSS and OS for very elderly patients. Therefore, for elderly patients aged ≥ 75 years who have HNC, conservative RT might be sufficient for treatment purposes.

Cited by 7 publications

References 28 publications

The role of age in treatment‐related adverse events in patients with head and neck cancer: A systematic review

The role of age in treatment‐related adverse events in patients with head and neck cancer: A systematic review

Factors Influencing Treatment Outcome of Non-Nasopharyngeal Head and Neck Squamous Cell Carcinoma in Geriatric Patients

Non-stereotactic radiotherapy in older cancer patients

Contact Info

Product

Resources

About